Recent Updates
Recently added Catalysts
GELS Positive Sentiment Score: 70/100

The Ne xt E v ol ut ion in O r al D ru g & N utr ien t Deli v e ry Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. INVESTOR OVERVIEW DECEMBER 2025 FORWARD LOOKING STATEMENTS Gelteq Limited 2025. All

Key Takeaway: Gelteq Limited is advancing its patented gel delivery platform that enhances drug absorption and bioavailability, potentially improving patient compliance through easier administration. They aim to address common challenges in the pharmaceutical and nutraceutical markets, such as poor adherence and pill fatigue by providing a more enjoyable method of consumption. With prospects for expansion into various drug classes, Gelteq positions itself strongly within a market projected to grow significantly over the next decade.

Market Sentiment Analysis

POSITIVE FACTORS

  • Gelteq's innovative gel delivery system shows a significant improvement in bioavailability, enhancing drug absorption by over 40%.
  • The company has a strong foundation for expanding its commercial scope across multiple drug classes.
  • The market opportunity for both pharmaceutical and nutraceutical sectors is promising, with robust growth forecasts.

Full Press Release Details

HUMAN HEALTH H u man Pha r mace ut ical H u man N utr ace ut ical ANIMAL HEALTH Animal Pha r mace ut ical Animal N utr ace ut ical 2024 2030 0 500 1000 1500 2000 2024 2034 0 500 1000 1500 2000 MARKET OPPORTUNITY ( HUMAN HEALTH ) The global p ha r mace ut ical ma r ke t Global n utr ace ut ical / supp lemen t ma r ke t $ 1 , 645.7 B $ 591.1 B 6.12 % CAGR 7.6 % CAGR $ 2 , 350.4 B $ 919.1 B So ur ce: G r and Vie w Re s ea r ch .
N . and Lim , E . J . , 2022. Iden t if y ing and add r e ss ing p ill a v e rs ion in ad u l ts w i t ho ut p h ys iological - r ela t ed d ysp hagia : A na rr a t i v e r e v ie w. B r i t i s h Jo ur nal of Clinical Pha r macolog y , 88 ( 12 ), pp.5128 - 5148. ** R u mo r e , M . M . and Vogenbe r g , F . R . , 2016. Bio s imila rs : st ill no t qu i t e r ead y fo r pr ime t ime .
Inc r ea s e p eak concen tr a t ion s The enhanced bioa v ailabili ty and sp eed of ab s o rpt ion pr o v ide s a str ong fo u nda t ion fo r a pp l y ing Gel t e q ' s p la t fo r m ac r o ss m u l t i p le o t he r oil - s ol u ble d ru g cla ss e s and add r e ss ing a ke y ind ustry need Plasma concentration Oil soluble drug in Gelteq gel Oil soluble drug Gelteq Limited 2025.
P r o v ide fa st e r ab s o rpt ion fo r an API Enhance ing r edien t ab s o rpt ion w hich can deli v e r s ignifican t l y im pr o v ed effec t i v ene ss of t he d ru g Inc r ea s e p eak concen tr a t ion s The demon str a t ed bioa v ailabili ty enhancemen ts b y a s ignifican t ma r gin pr o v ide s a str ong fo u nda t ion fo r a pp l y ing Gel t e q ' s p la t fo r m ac r o ss m u l t i p le o t he r w a t e r - s ol u ble d ru g cla ss e s , w i t h t he p o t en t ial t o e xp and t he Com p an y ' s comme r cial s co p e Graph = Gelteq trial results with a water soluble drug and FDA approved product GELTEQ ADVANTAGES - WATER SOLUBLE COMPOUNDS Plasma concentration Water soluble drug in Gelteq gel Water soluble drug with water time post - administration (hours) Gelteq Limited 2025.
Gel t e q ' s p a t en t ed gel deli v e ry can p o t en t iall y syst em s ol v e man y of t he p ha r mace ut ical and supp lemen t ind ustry ' s challenge s - f r om p oo r adhe r ence and p ill fa t ig u e t o t he o r al deli v e ry of in s ol u ble ing r edien ts O ur gel s can incl u de s ingle o r m u l t i p le w a t e r s ol u ble , fine in s ol u ble and oil - s ol u ble ing r edien ts Thi s can incl u de v i t amin s , mic r o and mac r o n utr ien ts , he r bal e xtr ac ts and ac t i v e p ha r mace ut ical ing r edien ts ( API s ), in a s ingle s helf - st able gel w i t h a u nifo r m t e xtur e and com p o s i t ion T r ial r e su l ts s ho w ed Gel t e q ' s inno v a t i v e t echnolog y fo r w a t e r s ol u ble com p o u nd s w a s able t o : Im pr o v e bioa v ailabili ty ( o v e r all ab s o rpt ion ) b y o v e r 40 % .
P . , Pen s on , P . E . , T s e , Y . , Abdelhafi z , M . A . , Ahmed , S . N . and Lim , E . J . , 2022. Iden t if y ing and add r e ss ing p ill a v e rs ion in ad u l ts w i t ho ut p h ys iological - r ela t ed d ysp hagia : A na rr a t i v e r e v ie w. B r i t i s h Jo ur nal of Clinical Pha r macolog y , 88 ( 12 ), pp.5128 - 5148. ** R u mo r e , M .
A global clinical and s cience ba s ed com p an y t ha t ha s de v elo p ed a no v el d ru g deli v e ry p la t fo r m in an inge st ible gel fo r m Gel t e q sp eciali z e s in t he fo r m u la t ion , de v elo p men t and man u fac tur ing of gel pr od u c ts fo r licen s ed p a rt ne rs Fo u nded in 2017 in Melbo ur ne , A ustr alia , t he com p an y eme r ged f r om i ts fo u nde rs ' w o r k a s a die t i t ian , aiming t o im pr o v e p a t ien t com p liance w i t h an ea sy t o sw allo w and enjo y able deli v e ry fo r ma t fo r medica t ion s and n utr i t ional supp lemen ts Gelteq Limited 2025.
Fo r a di s c uss ion of t he s e r i s k s and u nce rt ain t ie s , r efe r t o Gel t e q ' s filing s w i t h t he U . S . Sec ur i t ie s and E x change Commi ss ion (" SEC "), incl u ding i ts Ann u al Re p o rt on Fo r m 20 - F filed on No v embe r 17 , 2025. Gel t e q u nde rt ake s no obliga t ion t o up da t e an y fo rw a r d - looking st a t emen ts t o r eflec t e v en ts o r ci r c u m st ance s af t e r t he da t e he r eof .
All st a t emen ts , o t he r t han st a t emen ts of hi st o r ical fac t , con t ained he r ein a r e fo rw a r d - looking st a t emen ts. Fo rw a r d - looking st a t emen ts in v ol v e kno w n and u nkno w n r i s k s , u nce rt ain t ie s , and o t he r fac t o rs t ha t ma y ca us e ac tu al r e su l ts t o diffe r ma t e r iall y f r om t ho s e e xpr e ss ed o r im p lied in su ch st a t emen ts.

Frequently Asked Questions

What markets does Gelteq operate in?

Gelteq operates in the human and animal health markets, including pharmaceuticals and nutraceuticals.

What is the expected CAGR for nutraceutical markets?

The global nutraceutical market is projected to grow at a CAGR of 7.6%.

What is Gelteq's primary product delivery format?

Gelteq specializes in an ingestible gel format for drug delivery.

How does Gelteq improve drug absorption?

Gelteq's gel delivery system enhances absorption by over 40%, improving bioavailability.

When was Gelteq founded?

Gelteq was founded in 2017 in Melbourne, Australia.

Last updated: Dec 9, 2025